Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Noiiglutide Injection in Type 2 Diabetes Patients
NCT06649773Phase 3Completed
- Sponsor
- Hengrui
- Start
- Nov 2024
- Primary completion
- May 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of noiiglutide in type 2 diabetes mellitus (T2DM), sponsored by Hengrui. Started Nov 2024; status: completed.
02
Drugs
noiiglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06649773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06649773.